Bibliography
- MEUNIER PJ, ROUX C, SEEMAN E et al.: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl. Med. (2004) 350:459–468.
- SHANE E, ADDESSO V, NAMEROW PB et al.: Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl. I Med. (2004) 350:767–776.
- SIRIUS ES, MILLER PD, BARRETT-CONNOR E et al: Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. Results form the National Osteoporosis Risk Assessment. JA/VIA (2001) 286:2815–2822.
- MESSINGER-RAPPORT BJ, THACKER HL: Prevention for the older women, part 3: A practical guide to prevention and treatment of osteoporosis. Geriatrics (2002) 57:16–27.
- EL-HAJJ FG: Strontium ranelate - a novel therapy for osteoporosis or a permutation of the same. N Engl. I Med. (2004) 350:504–506.
- MARIE PJ: Optimizing bone metabolismin osteoporosis: insight into the pharmacological profile of strontium ranelate. Osteoporosis Int. (2003) 14\(Suppl. 3):59–512.
- BROWN EM: Is the calcium receptor a molecular target for the actions of strontium on bone? Osteoporos. mt. (2003) a14\(Suppl. 3):S25–S34.
- REGINSTER JY, DEROISY R, DOUGADOS M et al.: Prevention of early postmenopausal loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos. mt. (2002) 13:925–931.
- MEUNIER PJ, SLOSMAN DO, DELMAS PD et al.: Strontium ranelate: a dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized, placebo controlled trial. Clin. Endocrinol. Metab. (2002) 87:2060–2066.
- BLACK DM, GREENSPAN SL, ENSRU KE et al: The effects of parathyroid hormone and alendronate alone or in combination in post menopausal osteoporosis. N Engl. I Med. (2003) 349:1207–1215.
- FINKELSTEIN JS, HAYES A, HUNZELMAN JL et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl. I Med. (2003) 349:1216–1226.
- VAN CLEEMPUT J, DAENEN W, GEUSENS P et al.: Prevention of bone loss in cardiac transplant recipients. A comparison of bisphosphonates and vitamin D. Transplantation (1996) 61:1495–1499.
- STEMPFLE HU, WERNER C, ECHTLER S et al.: Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation (1999) 68:523–530.
- SAMBROOK P, HENDERSON NK, KEOGH A et al.: Effect of calcitriol on bone loss after cardiac or lung transplantation. I Bone Muter. Res. (2000) 15:1818–1824.
- SHANE E, RODINO MA, MCMAHON DJ et al.: Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. Heart. Lung. Transplant. (1998) 17:1089–1096.
- BRAITH RW, MAGYARI PM, FULTON MN et al:. Resistance exercise training and alendronate reverese glucocorticoid-induced osteoporosis in heart transplant recipients. I Heart. Lung. Transplant. (2003) 22:1082–1090.